Illimis Therapeutics

Seoul, South Korea · Founded 2021 · Privately Held (backing)

Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. Illimis Therapeutics is based in Seoul, South Korea and was founded in 2021. It has raised $64.3 million.

Last price · $/share
—
Implied valuation
—
Total raised
$64.3M
Last round
—

Who backs Illimis Therapeutics?

27 investors
InvestorType
Tech Incubator Program for StartupOther
Korea Development BankOther
IMM InvestmentAsset manager
Hana VenturesOther
STIC VenturesVenture capital
Schmidt (South Korea)Venture capital
T.S. InvestmentVenture capital
Woori Venture PartnersVenture capital
DAYLI PartnersVenture capital
LB InvestmentVenture capital
+ 17 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Illimis Therapeutics investors

27 investors are on record for Illimis Therapeutics, including Tech Incubator Program for Startup, Korea Development Bank, IMM Investment and Hana Ventures. By type, the record holds 8 venture capital firms and 1 hedge fund.

Free account
More of Illimis Therapeutics with a free account
  • ·The complete investor list: 27 names
  • ·Watch Illimis Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 27 firms already write checks for companies like Illimis Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View